2014-2020 Vaccine Deal Conclusion: Global Terms and Agreements, Agreement Trends, Actors and Financial Data – ResearchAndMarkets.com

DUBLIN – (COMMERCIAL THREAD) – The report “Global vaccine partnership terms and agreements 2014-2020: Trends in agreements, actors and financial data” has been added to ResearchAndMarkets.com offer.

The report provides comprehensive understanding and unprecedented access to partnership deals and vaccine deals made by the world’s leading healthcare companies.

• Trends in vaccine transactions in the biopharmaceutical industry since 2014

• Analysis of the structure of the vaccine agreement

• Access to title, advance, milestone and royalty data

• Access to over 1000 vaccine agreement documents

• The main vaccine offers by value since 2014

• The most active vaccine traders since 2014

• The main partnership resources for vaccines

This report contains a complete list of all vaccine partnership agreements announced since January 2014, including financial terms where available, including over 1000 links to online agreement files of partnership agreements actual vaccines as disclosed by the parties to the agreement. Additionally, when available, records include contractual documents as submitted to the Securities Exchange Commission by the companies and their partners.

In the report, the available contracts are listed by:

• Company from A to Z

• Title value

• Stage of development at signing

• Component type of the agreement

• Therapeutic target

• Specific type of technology

Each transaction title is linked via a web link to an online version of the transaction record and, if applicable, the contractual document, providing easy access to each contractual document on demand.

The report provides full access to available offers and contract documents for over 1,000 vaccine offers.

The analysis of actual contractual agreements makes it possible to assess the following elements:

• What are the specific rights to the vaccines granted or optional?

• What is actually granted by the agreement to the partner company?

• What exclusivity is granted?

• What is the payment structure for the transaction?

• How are sales and payments audited?

• How long is the agreement?

• How are the key terms of the agreement defined?

• How are IPRs managed and held?

• Who is responsible for marketing?

• Who is responsible for development, sourcing and manufacturing?

• How is confidentiality and publication managed?

• How to resolve disputes?

• Under what conditions can the deal be terminated?

• What happens in the event of a change of owner?

• What sub-licensing and subcontracting arrangements have been agreed?

• What standard clauses does the company insist on?

• Which standard clauses seem to differ from one partner to another or from one type of agreement to another?

• What jurisdiction does the company insist on for the law of agreements?

The report offers the reader the following main advantages:

• In-depth understanding of vaccine and adjuvant market trends since 2014

• Access to title, advance, milestone and royalty data

• Full access to over 1,000 vaccine contracts from global biopharmaceutical companies, as well as contract documents where available

• Detailed access to vaccine contracts concluded by the main biopharmaceutical companies

• Identify the main vaccine offers by value since 2014

• Identify the most active vaccine traders since 2014

• Overview of conditions included in a vaccine agreement

• Understand the key terms of agreements that companies have agreed to in previous agreements

• Undertake due diligence to assess the adequacy of the terms of your proposed agreement for partner companies

Companies mentioned

• 2A

• 3d drugs

• 3SBio

• 4D pharmacy

• Institute of Molecular and Cellular Biology A * STAR ‘

• ABEC

• ABIVAX

• AGC organic products

• Agenus Bio

• Agilvax

• AIM ImmunoTech

• Akers Biosciences

• Amyris

• Analytical biochemistry laboratories

• MG Angels

• Anixa Biosciences

• Battelle

• Batu organic products

• CCT Research

• Therapeutic Celldex

• Cellular biomedicine

• Celonic

• Diavax Biosciences

• Diaxonhit

• DNA script

• ADNtrix

• Dr Reddy’s laboratories

• Frederick National Laboratory for Cancer Research

• Fred Hutchinson Cancer Research Center

• Fujifilm

• GISCAD Foundation

• GlaxoSmithKline

• Hefei Sageland Biotechnology

• Helmholtz Zentrum München

• MinervaX

• Recipharm

• Sanofi

• Wyss Institute

• Xenetic Biosciences

• XstalBio

• Y-Organic

• Therapeutic Y-mAbs

• Yale University

• Yamaguchi University

• Yisheng Biopharma

• Zenoaq

• Zoetis

• Zolovax

• Zuellig Pharma China

• Zydus Cadila

• ZYUS Life Sciences

• and many others !

For more information on this report, visit https://www.researchandmarkets.com/r/cmrgks